卵巢癌患者TSGF与CA-125联合检测的临床应用评价  

Evaluation of Clinical Examination of Serum TSGF and CA125 in Ovarian Cancer

作　　者：齐心亮[1] 赵勇[1] 张萍[1] 薛荣利[1] 彭俊华[1] 

机构地区：[1]兰州军区兰州总医院检验科,甘肃兰州730050

出　　处：《甘肃科学学报》2009年第3期102-104,共3页Journal of Gansu Sciences

摘　　要：评价恶性肿瘤特异生长因子(TSGF)对卵巢癌诊断、疗效观察中的价值.分别测定115例正常妇女、68例卵巢良性肿瘤患者和92例卵巢癌患者、56例卵巢癌患者术后或治疗后的血清TS-GF、CA125水平.卵巢癌患者TSCF、CA125阳性率分别为88.0%、84.8%,联合测定阳性率为94.6%;56例术后患者中,有12例患者血清TSGF和CA125升高,被临床证实转移或复发.联合测定TSGF、CA125可提高卵巢癌的阳性诊断率,对疗效观察及术后监测,亦有帮助.To evaluate the value of serum tumor supplied group of factor （TSGF） in ovarian cancer diag- nosis and curative effect observation. The serum levels of TSGF and CA125 concentration were examined in 115 cases of normal women,68 cases of benign ovarian tumor,92 cases of ovarian cancer and 56 cases of o- varian cancer patients after treatment. The TSGF and CA125 positive rates of ovarian cancer patients were 88.0% and 84.8% respectively,and the positive rate of both united-detection was 94.6%. In 56 cases of patients with ovarian cancer patients after treatment,TSGF and CA125 were elevated in 12 patients, con- firmed by clinical to be recurrence and metastasis. The determination of united TSGF and CA125 can pro- mote positive rate of diagnosis of ovarian cancer, and be useful for postoperative observation and monitoring of efficacy

关 键 词：卵巢癌 TSGF CA-125 

分 类 号：R737.31[医药卫生—肿瘤] R446[医药卫生—临床医学]